Pasithea Therapeutics

Historical price data

Pasithea Therapeutics is a micro-cap biotech founded in 2020 with a mission to develop innovative treatments for CNS disorders and RASopathies. Its core strategy is the targeted application of MEK inhibitors, based on the scientific rationale that dysregulation of the RAS/MAPK pathway is a key driver in conditions like NF1, ALS, and MS. The company has assembled a leadership team with deep neuroscience and drug development expertise, led by renowned neurologist and immunologist Professor Lawrence Steinman. While still in the early stages of development with a preclinical/IND-enabling pipeline, Pasithea is targeting large, underserved markets with a mechanism-driven approach.

A targeted drug discovery platform centered on inhibiting the MEK protein within the RAS/MAPK signaling pathway, with applications in neuroinflammatory CNS disorders and genetic RASopathies.

Pasithea competes directly with AstraZeneca's approved selumetinib in NF1 and faces numerous advanced competitors in ALS and MS. Its schizophrenia approach is highly novel but trails behind other late-stage novel mechanisms. As a micro-cap company, its primary competitive disadvantage is a severe lack of financial resources.